α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote durable rejection and immunity in squamous cell carcinomas

Earlier this year UCSF post-doc Eswari Dodagatta, along with her co-authors and Akhurst lab colleagues, published in the Journal for ImmunoTherapy of Cancer. Check it out! @sitcancer #WomeninScience #WomenInImmunology https://t.co/K6yglD1Fy7

RT @gulleyj1: α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote…

RT @gulleyj1: α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote…

RT @gulleyj1: α-PD-1 therapy elevates Treg/Th balance and increases tumor cell pSmad3 that are both targeted by α-TGFβ antibody to promote…